CAPRICOR THERAPEUTICS, INC. 8-K

What Happened
Capricor Therapeutics, Inc. announced its financial results for the quarter and full year ended December 31, 2025 by issuing a press release on March 12, 2026. The company furnished the press release as Exhibit 99.1 to a Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The Form 8-K was signed by CEO Linda Marbán, Ph.D.

Key Details

• Filing date: March 12, 2026 (Form 8-K furnished to the SEC).
• Reporting period: Quarter and full year ended December 31, 2025.
• Exhibit: Press release titled “Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Corporate Update” furnished as Exhibit 99.1.
• Form sections: Item 2.02 (results announced) and Item 9.01 (exhibits); signed by Linda Marbán, Ph.D., Chief Executive Officer.

Why It Matters
This 8-K notifies investors that Capricor has released its quarterly and annual financial results and a corporate update — information that can affect the company’s valuation and near-term stock movement. Retail investors should review the attached press release for actual revenue, profit/loss, cash position, guidance, and management commentary to understand the financial performance and outlook.